Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$23.90 -1.0%	$20.93	$7.75 ▼ $27.17	$183.31M	0.68	44,661 shs	130,276 shs
CPIX Cumberland Pharmaceuticals	$3.63 -1.6%	$3.30	$1.04 ▼ $7.25	$54.31M	-0.37	632,902 shs	57,601 shs
JNJ Johnson & Johnson	$177.71 -0.2%	$167.02	$140.68 ▼ $181.16	$427.98B	0.4	8.97 million shs	6.83 million shs
LLY Eli Lilly and Company	$736.27 +0.1%	$747.03	$623.78 ▼ $954.00	$696.85B	0.47	4.15 million shs	2.22 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	-2.31%	-5.82%	+31.14%	+50.91%	+48.40%
CPIX Cumberland Pharmaceuticals	+5.73%	+8.53%	+4.83%	-33.27%	+173.33%
JNJ Johnson & Johnson	+0.40%	+0.67%	+6.26%	+15.92%	+7.21%
LLY Eli Lilly and Company	+0.29%	-0.05%	-3.53%	-4.20%	-23.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASMB Assembly Biosciences	3.305 of 5 stars	3.4	1.0	0.0	4.7	2.1	0.0	0.0
CPIX Cumberland Pharmaceuticals	1.0043 of 5 stars	0.0	3.0	0.0	0.0	3.8	1.7	0.0
JNJ Johnson & Johnson	4.6149 of 5 stars	2.3	3.0	4.2	3.9	2.9	1.7	1.9
LLY Eli Lilly and Company	5 of 5 stars	4.3	3.0	3.3	4.0	2.6	3.3	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.75	Moderate Buy	$38.67	61.95% Upside
CPIX Cumberland Pharmaceuticals	0.00	N/A	N/A	N/A
JNJ Johnson & Johnson	2.65	Moderate Buy	$176.29	-0.72% Downside
LLY Eli Lilly and Company	2.67	Moderate Buy	$950.17	29.15% Upside

Current Analyst Ratings Breakdown

Latest CPIX, ASMB, LLY, and JNJ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/21/2025	JNJ Johnson & Johnson	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$185.00 ➝ $200.00
8/19/2025	ASMB Assembly Biosciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/18/2025	ASMB Assembly Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$975.00 ➝ $825.00
8/13/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$942.00 ➝ $875.00
8/11/2025	LLY Eli Lilly and Company	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,010.00 ➝ $900.00

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$28.52M	6.42	N/A	N/A	$2.36 per share	10.12
CPIX Cumberland Pharmaceuticals	$37.87M	1.42	$0.27 per share	13.57	$1.85 per share	1.95
JNJ Johnson & Johnson	$88.82B	4.81	$13.15 per share	13.50	$32.58 per share	5.45
LLY Eli Lilly and Company	$45.04B	15.46	$14.29 per share	51.47	$19.39 per share	37.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$40.18M	-$5.58	N/A	N/A	N/A	-117.20%	-149.01%	-39.04%	11/6/2025 (Estimated)
CPIX Cumberland Pharmaceuticals	-$6.48M	-$0.22	N/A	∞	N/A	-6.97%	7.48%	2.66%	11/4/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$9.35	18.98	16.04	2.26	25.00%	32.49%	13.00%	10/21/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	48.11	23.64	1.02	25.91%	92.72%	16.89%	10/29/2025 (Estimated)

Latest CPIX, ASMB, LLY, and JNJ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	ASMB Assembly Biosciences	-$1.73	-$1.33	+$0.40	-$1.33	$5.30 million	$9.63 million
8/5/2025	Q2 2025	CPIX Cumberland Pharmaceuticals	N/A	$0.02	N/A	-$0.05	N/A	N/A
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	2.93%	N/A	55.61%	64 Years
LLY Eli Lilly and Company	$6.00	0.82%	N/A	39.22%	11 Years

Latest CPIX, ASMB, LLY, and JNJ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	1.64	1.64
CPIX Cumberland Pharmaceuticals	0.19	1.30	1.17
JNJ Johnson & Johnson	0.50	1.01	0.76
LLY Eli Lilly and Company	1.86	1.28	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
CPIX Cumberland Pharmaceuticals	15.51%
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	5.10%
CPIX Cumberland Pharmaceuticals	44.85%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	100	7.67 million	7.28 million	Optionable
CPIX Cumberland Pharmaceuticals	80	14.96 million	8.25 million	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable

CPIX, ASMB, LLY, and JNJ Headlines

Recent News About These Companies

Pharmaceutical Stocks To Follow Now - September 2nd

3 hours ago | marketbeat.com

Global drugmakers rush to boost US presence as tariff threat looms

4 hours ago | reuters.com

Jim Cramer Urges Patience With Eli Lilly and Company (LLY)’s Stock

4 hours ago | insidermonkey.com

Eli Lilly’s New Obesity Drug Study: Key Insights for Investors

5 hours ago | tipranks.com

Insider Watch: 3 CEOs Buying the Dip

5 hours ago | zacks.com

BMO Capital Markets Reaffirms ‘Buy Rating’ on Eli Lilly Stock (LLY)

September 3 at 12:10 PM | tipranks.com

Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly

September 3 at 9:30 AM | globenewswire.com

Eli Lilly and Company $LLY Shares Bought by Adage Capital Partners GP L.L.C.

September 3 at 7:41 AM | marketbeat.com

Eli Lilly and Company $LLY Stake Reduced by ADAR1 Capital Management LLC

September 3 at 7:41 AM | marketbeat.com

Eli Lilly and Company $LLY Shares Acquired by Federation des caisses Desjardins du Quebec

September 3 at 7:01 AM | marketbeat.com

Southpoint Capital Advisors LP Takes Position in Eli Lilly and Company $LLY

September 3 at 6:51 AM | marketbeat.com

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

September 2 at 5:32 PM | zacks.com

Jim Cramer Says This “Ridiculously Cheap” Healthcare Stock is a Buy

September 2 at 3:51 PM | 247wallst.com

Insiders Bought the Selloff in Eli Lilly. Should You Buy LLY Stock, Too?

September 2 at 3:31 PM | barchart.com

Confidence in Tectonic Therapeutic’s Strategic Approach Amid Eli Lilly’s Trial Setback

September 2 at 3:31 PM | tipranks.com

Promising Pharmaceutical Stocks To Keep An Eye On - September 1st

September 2 at 2:28 PM | marketbeat.com

BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects

September 2 at 1:10 PM | insidermonkey.com

Novo's Wegovy tops Lilly's Zepbound at curbing cardio risks in real-world study

September 2 at 12:43 PM | fiercepharma.comF

Lilly ends 2 of 3 midstage trials for oral GLP-1 contender naperiglipron

September 2 at 12:43 PM | fiercebiotech.comF

Stocks to Watch Tuesday: Nvidia, Eli Lilly, PepsiCo, AMD

September 2 at 12:43 PM | wsj.com

These 3 Companies are Seeing Supercharged Sales Growth

September 2 at 12:31 PM | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CPIX, ASMB, LLY, and JNJ Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$23.90 -0.23 (-0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$23.96 +0.06 (+0.25%)

As of 04:10 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.63 -0.06 (-1.63%)

Closing price 03:59 PM Eastern

Extended Trading

$3.57 -0.06 (-1.65%)

As of 05:13 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Johnson & Johnson NYSE:JNJ

$177.71 -0.35 (-0.20%)

Closing price 03:59 PM Eastern

Extended Trading

$177.70 0.00 (0.00%)

As of 05:08 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$736.26 +1.08 (+0.15%)

Closing price 03:59 PM Eastern

Extended Trading

$736.34 +0.08 (+0.01%)

As of 05:17 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time